Antimicrobial susceptibility patterns of clinical isolates of Staphylococcus aureus in Nepal  by Subedi, S. & Brahmadathan, K.N.
RESEARCH NOTE
Antimicrobial susceptibility patterns of
clinical isolates of Staphylococcus aureus
in Nepal
S. Subedi and K. N. Brahmadathan
Department of Microbiology, Manipal Teaching
Hospital, Pokhara, Nepal
ABSTRACT
Isolates of Staphylococcus aureus (n = 117) from
patients attending a tertiary care centre in western
Nepal were tested for susceptibility to penicillin,
oxacillin, gentamicin, erythromycin and ciproﬂ-
oxacin. Eighteen (15.4%) were methicillin-resist-
ant. Susceptibility among methicillin-resistant
isolates varied from 0% (penicillin) to 16.6%
(erythromycin and gentamicin), but varied among
methicillin-susceptible isolates from 39.4% (peni-
cillin) to 97.0% (ciproﬂoxacin). Fourteen (77.8%)
of the methicillin-resistant isolates were resistant
to all agents tested. Implementation of an appro-
priate antibiotic policy would reduce the risk of
further development of antimicrobial resistance.
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Staphylococcus aureus is capable of causing a
variety of human infections, including fatal inva-
sive and toxic conditions [1], and also possesses a
differential ability to spread and cause hospital-
associated outbreaks of infection [1,2]. The emer-
gence of methicillin-resistant S. aureus (MRSA)
strains with multidrug resistance has posed chal-
lenges in the treatment of infections [3]. These
strains do not possess additional virulence prop-
erties, nor are they more infectious than strains of
methicillin-susceptible S. aureus (MSSA), but their
characteristic multidrug resistance restricts the
options available to treat infections caused by
these organisms. Available alternative drugs are
often prohibitively costly or not readily available
in Nepal. Therefore, it is necessary to carry out
regular antimicrobial susceptibility testing on
isolates to provide data on which to base selection
of appropriate and affordable antibiotics.
In Nepal, especially in the more remote regions
of the country, the use of antimicrobial agents has
been minimal because of their unavailability or
the absence of medical care. Consequently, resist-
ance to antimicrobial agents has been slow to
develop in many bacteria associated with clinical
infections. This prompted a study of the antimi-
crobial susceptibility patterns of S. aureus, the
organism associated most frequently with clinical
infections in our hospital, which is a tertiary care
hospital in the western region of Nepal.
Isolates of S. aureus from diverse clinical sam-
ples from patients attending theManipal Teaching
Hospital, Pokhara, Nepal during the period Janu-
ary 2001 to January 2002 were included in this
study. Isolates were identiﬁed by their morphol-
ogy following Gram’s stain, colonial morphology
on blood agar and mannitol salt agar, and slide
and tube coagulase tests [1]. In total, 226 isolates of
S. aureus were recovered from various clinical
specimens during the study period, but the
unavailability or erratic supply of antimicrobial
disks meant that not all agents in the panel could
always be tested. Therefore, this report presents
results only for 117 isolates that were tested for
susceptibility to the following representatives of
four antimicrobial groups: penicillin, 10-U disks,
and oxacillin, 1-lg disks (b-lactams); gentamicin,
10-lg disks (aminoglycosides); erythromycin,
15-lg disks (macrolides); and ciproﬂoxacin, 5-lg
disks (quinolones). Antimicrobial susceptibility
testing was performed with the Kirby–Bauer disk
diffusion method on Mueller–Hinton agar [4,5],
with commercially available antimicrobial disks
(Hi Media, Mumbai, India).
Only 18 (15.4%) of the 117 isolates tested were
methicillin-resistant, as deﬁned by resistance to
oxacillin. This percentage is substantially lower
than that found in the Indian subcontinent, where
the reported prevalence has varied from 20% to
53% [6,7]. In a multicentre study in Pakistan,
Haﬁz et al. [8] found a prevalence rate varying
from 2% to 61%. In an earlier study from Nepal,
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Rai et al. [9] found that 29% of S. aureus isolates
were resistant to methicillin, although the method
of testing was different to that used in the present
study [10]. These studies stress the need to
monitor the prevalence of MRSA continuously
in a given population, because it can vary from
region to region.
The present study indicated a relatively high
rate of susceptibility among clinical isolates of
MSSA to b-lactam, aminoglycoside, macrolide
and quinolone agents (Table 1). Of 99 MSSA
isolates, 39% were susceptible to penicillin and
> 94% were susceptible to other agents, which is a
much higher rate of susceptibility than that
reported from neighbouring countries [6,11–13].
As reported elsewhere [13,14], the MRSA iso-
lates were commonly resistant to other agents
(Table 1), with £ 17% susceptible to any other
agent tested; most showed multidrug resistance,
with 78% of the 18 MRSA isolates showing
resistance to all other agents tested (Table 2).
However, susceptibility to gentamicin and eryth-
romycin among MRSA isolates was higher than
reported from neighbouring countries [13], and
these agents might be used to treat MRSA
infections if isolates are shown to be susceptible.
Among the MSSA isolates, multidrug resistance
was uncommon, with no isolate resistant to all
agents tested, and 39 (39.4%) isolates susceptible
to all agents tested (Table 2).
Among alternative agents that might be con-
sidered for treatment of MRSA infections, vanco-
mycin was not tested routinely in the present
study; indeed, cost and availability may prohibit
its use in our hospital. Studies in Vellore in India
[15] have shown higher rates of susceptibility to
netilmicin and rifampicin and, although not
tested routinely, these may be cost-effective drugs
to treat infections caused by MRSA in this region.
Our hospital is a large tertiary care centre, and
the patients include those from remote areas of
Nepal. Medical facilities are virtually non-existent
in many such areas, where most patients have
never been exposed to antimicrobial agents
because of their unavailability or high cost, and
the absence of proper medical care. This may be
responsible for the high rates of antimicrobial
susceptibility among many pathogenic bacteria
isolated from clinical infections seen in our
hospital. In such a setting, implementation of
an appropriate antibiotic policy should help
substantially to control the emergence of drug
resistance in the future. This study also under-
scores the importance of choosing cost-effective
agents, based on the results of antimicrobial
susceptibility testing. Lack of resources and
laboratory reagents may not permit antimicrobial
susceptibility testing of every organism isolated,
but the generation of sufﬁcient laboratory-based
data will help in the formulation of an appropri-
ate antibiotic policy.
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ABSTRACT
This study compared MIC distributions of
amoxycillin–clavulanate obtained with NCCLS
and French (Comite´ de l’Antibiogramme de la
Socie´te´ Franc¸aise de Microbiologie; CA-SFM)
methodologies for Escherichia coli isolates from
urine that were non-susceptible to amoxycillin–
clavulanate by the disk diffusion method. With
the NCCLS and CA-SFM methods, 74% and 13%,
respectively, of these isolates were susceptible to
amoxycillin–clavulanate. Therefore, the apparent
relatively poor efﬁcacy of amoxycillin–clavula-
nate against E. coli in French hospitals probably
reﬂects a methodological difference rather than a
localised resistance problem. This implies that
amoxycillin–clavulanate could be used as an
alternative to ﬂuoroquinolones for treatment of
E. coli urinary tract infections. Susceptibility tests
for amoxycillin–clavulanate should be standard-
ised worldwide.
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Escherichia coli is the bacterial pathogen isolated
most frequently from clinical samples taken for
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